Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | TK1 | P04183 | 3/20 | 0.46 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.46 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | TK2 | O00142 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4214655 | 1.00 | LMNA (0.49) | LMNASMN1; SMN2TK1ADRB1DNMT1 | |
| SCHEMBL29388908 | 0.78 | LMNA (0.49) | LMNASMN1; SMN2TK1ADRB1DNMT1 | |
| SCHEMBL16378861 | 0.78 | LMNA (0.49) | LMNASMN1; SMN2TK1ADRB1DNMT1 | |
| SCHEMBL20463353 | 0.77 | LMNA (0.50) | LMNASMN1; SMN2TK1ADRB1DNMT1 | |
| SCHEMBL5193538 | 0.75 | LMNA (0.46) | LMNASMN1; SMN2TK1ADRB1DNMT1 | |
| SCHEMBL8600543 | 0.75 | CDA (0.47) | LMNASMN1; SMN2DNMT1BLMPMP22 | |
| SCHEMBL8600538 | 0.75 | CDA (0.47) | LMNASMN1; SMN2DNMT1BLMPMP22 | |
| SCHEMBL27041390 | 0.74 | LMNA (0.46) | LMNASMN1; SMN2TK1ADRB1DNMT1 | |
| SCHEMBL22978936 | 0.73 | LMNA (0.44) | LMNASMN1; SMN2TK1ADRB1DNMT1 | |
| SCHEMBL9353684 | 0.73 | LMNA (0.44) | LMNASMN1; SMN2TK1ADRB1DNMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1418949-B1 | INHIBITOR OF DNA METHYLATION | OREGON STATE (US) | 2013-06-19 | — | — | EP | disclosed |
| US-8207142-B2 | Using zebularine; prevent, reverse methylation of nucleic acids ; antitumor agents; antiproliferative agents; antitumor agents; anticancer agents | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2012-06-26 | — | — | US | disclosed |
| EP-1418949-A4 | INHIBITOR OF DNA METHYLATION | OREGON STATE (US) | 2009-03-04 | — | — | EP | disclosed |
| US-20050119201-A1 | Inhibitor of dna methylation | UNIVERSITY OF MIAMI | 2005-06-02 | — | — | US | disclosed |
| EP-1418949-A2 | INHIBITOR OF DNA METHYLATION | THE STATE OF OREGON acting by and through THE STATE BOARD OF HIGHER EDUCATION on behalf of THE UNIVERSITY OF OREGON (US) | 2004-05-19 | — | — | EP | disclosed |
| WO-2003035844-A9 | NOVEL HISTONE METHYLTRANSFERASE AND METHODS OF ITS USE | OREGON STATE (US) | 2004-05-13 | — | — | WO | disclosed |
| US-20040086911-A1 | Inhibition of gene expression in vertebrates using double-stranded RNA (RNAi) | BAYLOR COLLEGE OF MEDICINE | 2004-05-06 | — | — | US | disclosed |
| WO-2004001013-A2 | INHIBITION OF GENE EXPRESSION IN VERTEBRATES USING DOUBLE-STRANDED RNA (RNAI) | BAYLOR COLLEGE OF MEDICINE (US) | 2003-12-31 | — | — | WO | disclosed |
| WO-2003035844-A2 | NOVEL HISTONE METHYLTRANSFERASE AND METHODS OF ITS USE | THE STATE OF OREGON ACTING BY AND THROUGH THE STATE BOARD OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF OREGON (US) | 2003-05-01 | — | — | WO | disclosed |
| WO-2003012051-A2 | INHIBITOR OF DNA METHYLATION | THE STATE OF OREGON ACTING BY AND THROUGH THE STATE BOARD OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF OREGON (US) | 2003-02-13 | — | — | WO | disclosed |
| WO-2003012052-A2 | SPECIFIC INHIBITION OF GENE EXPRESSION BY SMALL DOUBLE STRANDED RNAS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2003-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119201-A1 | Inhibitor of dna methylation | DNMT1, DNMT3B, DNMT3L | LMNA 368/4885SMN1; SMN2 2710/4885TK1 332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.